Nucleic Acid Therapeutics Patents

RNA interference therapeutics are built on a complex patent landscape that originated with Fire & Mello's 2006 Nobel Prize work — with commercialization dominated by Alnylam Pharmaceuticals and a growing number of competitors: MAJOR siRNA / RNAi PATENT HOLDERS: ALNYLAM PHARMACEUTICALS: 1,000+ patents; FOUNDATIONAL RNAi IP: specific RNAi trigger design (specific 19-21 nt siRNA duplex with specific 2-nt 3' overhang for specific RISC complex loading; specific chemical modifications: specific 2'-OMe + 2'-F alternating modification for specific serum stability + immunogenicity reduction); APPROVED DRUGS: patisiran (ONPATTRO — first FDA-approved RNAi drug 2018; specific siRNA targeting TTR mRNA + specific lipid nanoparticle formulation MC3 ionizable lipid); givosiran (GIVLAARI — specific ALA synthase siRNA + specific GalNAc conjugate for specific hepatocyte targeting); lumasiran (OXLUMO — specific HAO1 siRNA + specific GalNAc); inclisiran (Novartis licensing — specific PCSK9 siRNA + specific GalNAc for specific LDL-C reduction with specific twice-yearly dosing); vutrisiran (AMVUTTRA — specific TTR siRNA + specific GalNAc for specific improved dosing vs. patisiran); GALACTOSAMINE (GalNAc) CONJUGATE IP: specific triantennary GalNAc conjugate targeting specific asialoglycoprotein receptor (ASGPR) for specific hepatocyte-selective RNAi delivery without LNP — Alnylam ESC (Enhanced Stabilization Chemistry) platform; SILENCE THERAPEUTICS: specific AtuRNAi (specific blunt-end siRNA with specific modified ribose for specific 2-2-2 pattern); ARROWHEAD PHARMACEUTICALS: specific ARO-HBV; specific TRiM platform (specific targeted RNAi molecule); DICERNA PHARMACEUTICALS (ACQUIRED NOVO NORDISK): specific GalXC RNAi (specific GalNAc + specific extended-RNA lipid nanoparticle for specific liver delivery); SIRNAOMICS: specific PolyDisc siRNA delivery platform.

Lipid nanoparticle (LNP) delivery is one of the most critical and contested IP areas in nucleic acid therapeutics — where specific ionizable lipid compositions; formulation methods; and particle characteristics create patentable innovations: LNP DELIVERY PATENT LANDSCAPE: ALNYLAM / ARBUTUS BIOPHARMA (LNP PATENT DISPUTE): specific MC3 ionizable lipid (DLin-MC3-DMA) for specific siRNA LNP (patisiran LNP; specific pKa ~6.44 enabling specific endosomal escape; Alnylam licensed from Arbutus 2012 for siRNA; Arbutus claimed broader LNP patents cover Moderna mRNA LNPs); ARBUTUS vs. MODERNA LNP PATENT DISPUTE: Arbutus challenged Moderna mRNA COVID vaccine LNP patents claiming their earlier LNP patents cover Moderna formulation; IPR proceedings at USPTO; significant ongoing litigation as of 2025; MODERNA: 500+ mRNA patents; specific SM-102 ionizable lipid (heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate) for specific mRNA-1273 COVID vaccine LNP; specific LNP formulation (specific ionizable lipid + specific DSPC + specific cholesterol + specific PEG-lipid at specific molar ratios for specific particle size + specific encapsulation efficiency + specific hepatic vs. extra-hepatic tissue targeting); specific mRNA cap structure (specific CleanCap m7G(5')ppp(5')NmpNmpN trinucleotide cap for specific translational efficiency); BIONTECH: specific Acuitas LNP license (A0-45-2 ionizable lipid in Pfizer-BioNTech BNT162b2); PFIZER: specific BNT162b2 modified mRNA (specific N1-methylpseudouridine m1Ψ modification for specific innate immune evasion + specific mRNA stability); specific formulation lipid composition; ACUITAS THERAPEUTICS: specific ionizable lipid library IP for non-hepatic LNP delivery (specific lung + spleen + lymph node targeting by specific formulation modification); PRECISION NANOSYSTEMS (BIO-RAD ACQUISITION): specific microfluidic mixing chip for specific LNP manufacturing at specific scale; ARCTUS BIOTHERAPEUTICS: specific SORT (selective organ targeting) technology for specific extra-hepatic LNP delivery via specific lipid component addition; GENEVANT SCIENCES (ARBUTUS SPINOUT): specific LNP formulation IP for licensing.

Antisense oligonucleotides and CRISPR gene editing represent the two other major branches of the nucleic acid therapeutics IP landscape — each with distinct patent structures and commercial implications: ANTISENSE OLIGONUCLEOTIDE (ASO) PATENT LANDSCAPE: IONIS PHARMACEUTICALS (FORMERLY ISIS): 1,000+ ASO patents; dominant ASO IP position: FOUNDATIONAL ASO CHEMISTRY: specific phosphorothioate backbone (PS backbone: specific P=S substitution for specific nuclease resistance + specific plasma protein binding + specific RNase H activity); specific LNA (locked nucleic acid) modification (Exiqon/Roche licensing): specific 2'-4' bridging for specific binding affinity + specific thermal stability improvement; specific GapmerS (specific 2'-modified wings + specific PS DNA gap for specific RNase H activity + specific specificity); specific constrained ethyl (cEt) BNA modification; APPROVED IONIS ASO DRUGS: nusinersen (SPINRAZA — first ASO drug FDA approved 2016; specific antisense targeting specific SMN2 pre-mRNA splice site for specific SMN protein restoration in SMA); inotersen (TEGSEDI — specific TTR mRNA knockdown); tofersen (QALSODY — specific SOD1 ASO for specific ALS); SPLICE-SWITCHING OLIGONUCLEOTIDES (SSOs): specific exon-skipping for Duchenne muscular dystrophy (specific dystrophin exon 51 skipping — eteplirsen Sarepta; specific exon 53 skipping — golodirsen; specific PMO morpholino backbone chemistry Sarepta — specific non-ionic backbone for specific cardiac + skeletal muscle uptake without transfection); CRISPR IP LANDSCAPE: THE FOUNDATIONAL DISPUTE — BROAD INSTITUTE vs. UC BERKELEY: BROAD INSTITUTE (MIT/HARVARD; DAVID LIU; FENG ZHANG): specific Cas9 in eukaryotic cells (US8,697,359 — first eukaryotic CRISPR patent granted 2014); UC BERKELEY (DOUDNA/CHARPENTIER — 2020 Nobel Prize): specific biochemical mechanism + prokaryotic Cas9 activity; CURRENT STATUS (2025): Broad holds key eukaryotic CRISPR-Cas9 patents (US 8,697,359; US 8,771,945; US 8,795,965); UC Berkeley holds foundational biochemical patents; licensing required from both for commercial eukaryotic application; Editas Medicine (Broad spinout); Intellia Therapeutics (Caribou Biosciences/Doudna-linked); CRISPR Therapeutics (Charpentier-linked); EX VIVO vs. IN VIVO: ex vivo (cell therapy): CAR-T editing (CRISPR Therapeutics CTX001 = casgevy; Vertex; first FDA-approved CRISPR therapy 2023); in vivo: Intellia NTLA-2001 (specific transthyretin ATTR in vivo CRISPR + LNP liver delivery); BASE EDITING (David Liu Broad; Beam Therapeutics): specific cytosine base editor (CBE) converting C→T; specific adenine base editor (ABE) converting A→G without double-strand break; PRIME EDITING (David Liu; Prime Medicine): specific pegRNA + specific RT domain fusion for specific search-and-replace editing.

RNA therapeutics and nucleic acid drug startups operate in one of the most patent-intensive and litigation-active areas in biotechnology — where fundamental delivery; chemistry; and target IP can determine company viability: RNA THERAPEUTICS STARTUP IP STRATEGY: UNDERSTAND THE NUCLEIC ACID IP LANDSCAPE: LNP PATENT THICKET: multiple parties claim foundational LNP IP (Arbutus; Alnylam; Moderna; Acuitas) = freedom-to-operate requires comprehensive LNP FTO analysis before any LNP-based product development; specific ionizable lipid composition must be differentiated from known IP to avoid dominating claims; CRISPR LICENSING REQUIRED: any eukaryotic CRISPR-Cas9 application requires licenses from Broad Institute (Editas) + potentially UC Berkeley (Caribou) — determine licensing costs early; alternative nucleases (Cas12; Cas13; base editor; prime editor) have different IP landscapes; GalNAc LIVER DELIVERY: Alnylam GalNAc conjugate IP is dominant for liver-targeted siRNA; new entrants must either license or develop differentiated delivery chemistry; WHAT IS PATENTABLE IN RNA THERAPEUTICS: NOVEL DELIVERY CHEMISTRY: specific novel ionizable lipid composition with specific measured pKa + specific measured encapsulation efficiency + specific measured tissue tropism that differs from known ionizable lipids (MC3; SM-102; ALC-0315; Lipid H); specific novel LNP formulation with specific measured particle size + PDI + mRNA expression in specific target tissue; NOVEL siRNA CHEMISTRY: specific novel chemical modification pattern on specific RNA sequence positions with specific measured serum stability + specific measured potency (IC50) improvement vs. unmodified; NOVEL ASO CHEMISTRY: specific novel backbone modification + specific bridging chemistry with specific measured affinity (Tm) + specific RNase H activity measurement; NOVEL TARGET SEQUENCE: specific novel siRNA/ASO sequence for specific novel target + specific clinical indication (if target is validated); TRADE SECRETS IN RNA THERAPEUTICS: specific ionizable lipid synthesis route; specific LNP manufacturing process parameters (flow rate ratio; total flow rate; lipid concentration; buffer conditions); specific GalNAc conjugate synthetic route; trained toxicity prediction model; REGULATORY STRATEGY: IND filing for RNA drugs requires extensive CMC data = publication trigger; file provisionals before any IND-required data becomes public; KEY FTO CONSIDERATIONS: LNP: Arbutus/Genevant + Alnylam/Arbutus license + Acuitas + Moderna SM-102; GalNAc: Alnylam ESC platform; siRNA CHEMISTRY: Alnylam ESC + Ionis cEt + Exiqon LNA; CRISPR: Broad eukaryotic + UC Berkeley biochemical; Beam/Prime Medicine base + prime editing; APPROVED DRUG COMPOSITION: patisiran TTR siRNA; givosiran ALA synthase siRNA; nusinersen SMN2 ASO; casgevy CRISPR CTX001 beta-thalassemia + SCD.